BRCA2 and serous adenocarcinoma: Although OCs of patients without a germline BRCA1 or BRCA2 mutation were selected based on their reported serous histology, revision revealed that 13% of these patients did not develop low‐ or high‐grade serous carcinomas (seven out of 54).